Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

Iovance Biotherapeutics Appoints Wendy L. Dixon,

Ph.D., to Board of Directors

SAN CARLOS, Calif., June 13, 2022 -- Iovance

Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor

infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the

company's Board of Directors, effective June 10, 2022. Dr. Dixon has more than 40 years of experience in the biopharmaceutical

industry, building and leading organizations and launching and growing more than 20 major global pharmaceutical products, including many

highly successful multibillion dollar global brands.

Iain Dukes, D. Phil., Chairman of the Board of Directors of Iovance,

stated, "Wendy has a successful track record in commercial leadership and new product launches, as well as a strong reputation for

strategic thinking and executional focus. She is also skilled in directing the interface between R&D and marketing to align the needs

of key stakeholders. Iovance is fortunate to have Wendy join our board as we prepare to submit our first BLA and transition into a fully-integrated

commercial organization with a rich development pipeline."

"I am thrilled to join the Iovance board during this important

journey toward commercialization and pipeline innovation," said Dr. Dixon. "Iovance TIL therapy has the potential to

become an important new class of cancer treatment to address unmet needs for patients. I am also excited about the Iovance immuno-oncology

pipeline, with many opportunities to expand current TIL therapies and develop new and next-generation cell therapies."

Dr. Dixon previously served as Chief Marketing Officer and President,

Global Marketing for Bristol-Myers Squibb (BMS) from 2001 to 2009. She led the global commercialization and launch strategy of eight new

products and directed growth and life cycle management for in-line brands. As a member of the Executive Committee at BMS, she was deeply

involved with the strategy and activities that transformed BMS into highly successful Specialty Biopharmaceutical company. Dr. Dixon

also established and served as the executive sponsor for the BMS "Women's Affinity Network," focused on gender diversity

and inclusion priorities.

From 1996 to 2001, Dr. Dixon was Senior Vice President, Marketing

at Merck & Co., where she was responsible in launching six new products. Previously, Dr. Dixon held executive management

positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline)

in marketing, regulatory affairs, project management and as a biochemist. She currently serves on the Boards of Directors of Alkermes

Plc, Arvinas, Inc. and Black Diamond Therapeutics, Inc. Previously, Dr. Dixon served on the Boards of Directors of Incyte

Corporation, bluebird bio, Inc., Dentsply International, Furiex Pharmaceuticals, Orexigen Therapeutics, Sesen Bio, Inc. (formerly

Eleven Biotherapeutics, Inc.), Ardea Biosciences, Inc. and Voyager Therapeutics, Inc. Dr. Dixon earned a B.Sc., an

M.Sc. in Natural Science, and a Ph.D. in Biochemistry at the University of Cambridge, UK.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to be the global leader in innovating,

developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational

approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient.

Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time

cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid

tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life

for patients with cancer. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking

statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us,"

or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written

or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended

to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some

cases, use terms such as "predicts," "believes," "potential," "continue," "estimates,"

"anticipates," "expects," "plans," "intends," "forecast," "guidance,"

"outlook," "may," "could," "might," "will," "should" or other

words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements

are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions,

expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as

of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information,

future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties

and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements

and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors

that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described

in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent

Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial

known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing

of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration ("FDA") or other

regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize

any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety

results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups

within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within

those trials based on FDA and other regulatory agency input; the changing landscape of care for cervical cancer patients may impact our

clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future

clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our

clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance

by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture

our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of

clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that

unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other

factors, including general economic conditions and regulatory developments, not within our control.

Iovance Biotherapeutics, Inc.:

Sara Pellegrino, IRC

Vice President, Investor Relations & Public Relations

650-260-7120 ext. 264

Director, Investor Relations & Public Relations